Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170012/S031

HEMOBLAST Bellows

Dilon Technologies, Inc. · Decision date Apr 28, 2026

FDA DECISIONP170012/S031

What did the FDA approve?

FDA records P170012/S031 as a supplement to PMA P170012, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Apr 28, 2026.

FDA approval order statement

approval for removal of the urological exception from the currently approved indications for use.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
General, Plastic Surgery
Decision date
Apr 28, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P170012/S031
Regulatory pathway
PMA supplement
Product code
PMX
Decision code
APPR
Decision date
Apr 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Absorbable collagen hemostatic agent with thrombin.

Product code
PMX
FDA device class
3

For the original device and its historical approval scope, see PMA P170012. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P170012 · Original PMA

    HEMOBLAST Bellows

  2. P170012/S031 received

    Application receipt date recorded by FDA.

  3. P170012/S031 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P170012. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170012

Product / regulatory recordCompanyPathwayDecision dateSource
Dilon Technologies, Inc.PMA approvalDec 15, 2017FDA
HEMOBLAST BellowsP170012/S032
Dilon Technologies, Inc.PMA supplementSep 3, 2026FDA

Explore the linked device profile

Other records with product code PMX

Product / regulatory recordCompanyPathwayDecision dateSource
Baxter Healthcare CorpPMA supplementNov 13, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Dilon Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
12050 Jefferson Ave., Suite 340, Newport News, VA, 23606

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records